Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript February 29, 2024 4:30 PM ET
Company Participants
Sherry Aulin - CFO
Ian Mortimer - President and CEO
Chris Kenney - CMO
Chris Von Seggern - CCO
Conference Call Participants
Paul Matteis - Stifel
Leonid Timashev - RBC Capital Markets
Tess Romero - JPMorgan
Andrew Tsai - Jefferies
Danielle Brill - Raymond James
Joseph Thome - TD Cowen
Brian Skorney - Baird
Marc Goodman - Leerink Partners
Laura Chico - Wedbush Security
Operator
Good afternoon. My name is Janie, and I will be your conference operator today. I would like to welcome you to the Q4 2023 Xenon Pharmaceuticals, Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, will be a question-and-answer session. [Operator Instructions] I would now like to turn the conference over to Sherry Aulin, Chief Financial Officer. You may begin your conference.
Sherry Aulin
Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's fourth quarter and full year 2023 financial and operating results. Joining me today are Ian Mortimer, Xenon's President and Chief Executive Officer; Dr. Chris Kenney, Xenon's Chief Medical Officer; and Dr. Chris Von Seggern, Xenon's Chief Commercial Officer.
Ian will begin with a summary of our recent progress in areas of focus for 2024. Chris Kenney will provide an overview of our ongoing XEN1101 clinical programs, including our plans in major depressive disorder, or MDD, and Chris Van Seggern will comment on key findings from our market research on the potential of XEN1101 in the MDD treatment landscape. I will close with a summary of our financial results and anticipated milestone events before opening the call up to your questions.
Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from our and our collaborators' clinical trials, the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of our and our partners' product candidates, the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in our XEN1101 and other development programs, the timing and results of our interactions with regulators, our ability to successfully develop and obtain regulatory approval of XEN1101 and our other product candidates, anticipated enrollment in our clinical trials and the timing thereof, and our expectation that we will have sufficient cash to fund operations into 2027. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statements.